FindTrial
Sign In

A study to know the efficacy of dexmeditomidine as an anti shivering agent after spinal anaesthesia.

A STUDY TO KNOW THE EFFICACY OF DEXMEDETOMIDINE AS AN ANTI SHIVERING AGENT FOLLOWING SPINAL ANAESTHESIA IN ADULTS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/02/039937
Enrollment
80
Registered
2022-02-02
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Group A - Dexmedetomidine Dose- 1mcg/kg over 20min: Dexmedetomidine is a potent and highly selective α2-adrenoceptor agonist with sympatholytic, sedative, amnestic,6 and analgesic7 pro

Sponsors

Dr Reema Rajshekhar Wali
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.ASA physical status I and II. 2.Age between 18 to 65 years. 3.Patient undergoing surgeries under spinal anaesthesia.

Exclusion criteria

Exclusion criteria: 1.Allergic to the study drugs-bupivacaine and dexmedetomidine 2.A Pre-Operative baseline temperature of more than 37.5 degreeCelsius 3.Patients on long standing opioids 4.Patients suffering from thyroid disorders 5.Patient undergoing surgeries like TURP, where irrigation fluids are used

Design outcomes

Primary

MeasureTime frame
1.To study the efficacy of dexmedetomidine in prevention of shivering in adult patients undergoing surgeries under spinal anaesthesiaTimepoint: 10 minutes from Time of Spinal Injection to 180 minutes—

Secondary

MeasureTime frame
To know the side effects of dexmedetomidineTimepoint: From time of Spinal Injection to 180 minutes—

Countries

India

Contacts

Public ContactDr Gajendra Singh

HKE Societys M R Medical College

gajendra.glb@gmail.com9886252233

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026